Enliven Therapeutics ELVN Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's short- and long-term operating lease liabilities?
- Enliven Therapeutics (ELVN) reported short- and long-term operating lease liabilities of -$97K in Q1 2026.
- How has Enliven Therapeutics's short- and long-term operating lease liabilities changed year-over-year?
- Enliven Therapeutics's short- and long-term operating lease liabilities decreased by 40.6% year-over-year, from -$69K to -$97K.
- What is the long-term trend for Enliven Therapeutics's short- and long-term operating lease liabilities?
- Over 2 years (2023 to 2025), Enliven Therapeutics's short- and long-term operating lease liabilities has grown at a 4.3% compound annual growth rate (CAGR), from -$310K to -$337K.